시장보고서
상품코드
2070315

위암 치료제 시장 규모와 예측(2021-2034년), 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 범위 : 종류별, 치료법별, 투여 경로별, 유통 채널별, 지역별

Stomach Cancer Therapeutics Market Size and Forecast 2021 - 2034, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Treatment, Route of Administration, Distribution Channel, and Geography

발행일: | 리서치사: 구분자 The Insight Partners | 페이지 정보: 영문 341 Pages | 배송안내 : 즉시배송

    
    
    



가격
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.
US $ 4,450 금액 안내 화살표 ₩ 6,928,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,450 금액 안내 화살표 ₩ 10,042,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,450 금액 안내 화살표 ₩ 13,155,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

위암 치료제 시장 규모는 2025년 53억 2,000만 달러에서 2034년까지 144억 6,000만 달러로 확대될 것으로 예상되고, 2026년부터 2034년까지 CAGR 11.76%를 기록할 것으로 전망됩니다.

전 세계 위암 발병률의 증가, 병용요법에서 PD-1/PD-L1 체크포인트 억제제의 급속한 보급, 그리고 바이오마커 기반 검사 및 동반진단의 확대는 위암 치료제 시장 규모 확대에 기여하는 주목할 만한 요인입니다. 또한, 종양에 대한 표적성을 높이기 위한 항체약물접합체(ADC)의 광범위한 도입, 이중 표적 및 이중 특이성 면역요법의 부상, 그리고 맞춤형 치료 경로를 위한 AI 및 멀티오믹스의 본격적인 도입이 가까운 미래에 위암 치료제 시장에 새로운 동향을 가져올 것으로 예측됩니다.

위암은 발병 과정에 다양한 유전체, 전사체, 단백체 및 후성유전학적 요인이 관여하기 때문에 복잡한 생물학적 양상을 보이며, 표준 치료법만으로는 충분한 효과를 얻기 어려운 경향이 있습니다. 다중오믹스 통합을 통해 연구자들은 종양의 생물학적 특성에 대한 종합적인 인사이트를 얻을 수 있으며, 이를 통해 의사가 표적 치료법을 선택할 때 활용하는 HER2, PD-L1, CLDN18.2 등의 중요한 바이오마커를 규명할 수 있게 됩니다. AI를 활용함으로써 연구자들은 방대한 멀티오믹스 데이터세트를 분석하여 패턴을 발견하거나 치료 결과를 예측할 수 있게 됩니다. AI 모델을 활용함으로써 연구자들은 바이오마커의 수준이나 분자적 특성에 따라 환자를 분류하고, ADC 치료와 면역요법 중 어느 쪽을 선택해야 할지 판단할 수 있게 됩니다. 현재, 기계 학습 기법은 ADC 개발 과정에서 연구자들을 지원하고 있으며, 안정적인 링커를 유지하면서 효과적인 항체를 선별하고 강력한 페이로드를 창출함으로써, 약물 설계의 효율성과 임상시험의 성공률을 높이고 있습니다. AI를 활용한 임상 의사결정 지원 시스템을 통해 의료 종사자는 유전자 데이터 및 치료 이력을 포함한 환자별 정보를 바탕으로 가장 효과적인 치료 방안을 결정할 수 있습니다. 이는 HER2 억제제나 면역관문억제제 등의 치료에 대한 내성이 흔히 나타나는 위암의 경우, 특히 중요합니다. AI 시스템은 지속적인 학습을 통해 치료 경로를 개선하고, 적응성이 높은 치료법 개발에 기여합니다.

AI 기술과 멀티오믹스 연구가 연계됨으로써, 위암에 대한 정밀 종양학이 실현됩니다. 이를 통해 의사는 보다 정확한 진단을 내리고, 맞춤형 치료 프로그램을 통해 환자의 예후를 개선하는 표적 치료를 제공할 수 있게 되었으며, 이는 위암 치료 시장에서 중요한 추세로 부상하고 있습니다.

유통 채널별 분석

유통 채널에 따라 위암 치료제 시장은 병원 약국, 소매 약국, 온라인 약국으로 구분됩니다. 2025년에는 병원 약국 부문이 위암 치료제 시장에서 가장 큰 점유율을 차지했습니다. 병원 약국은 임상 환경에서 투여해야 하는 고가이며 복잡한 항암제의 조제를 담당하고 있습니다. 이 약국들은 화학요법, 면역요법, 표적요법 치료를 시행하는 병원 내 업무를 통해 종양내과 전문의 및 다학제 전문가들로 구성된 종양 회진, 정맥주사 센터와 긴밀히 협력하고 있습니다. 이 시스템은 특별한 보관 방법이나 환자의 상시 관찰이 필요한 주사제나 비경구용 약물을 취급할 때 그 진가를 발휘합니다. 병원 약국은 처방약 목록 선정, 의약품 안전성 감시 및 조달 활동을 통해 첨단 치료제의 모든 측면을 관리하고 있습니다. 시장 확대는 위암 환자 수의 증가, 종양과 확대, 그리고 임상적 감독이 필요한 생물학적 제제 및 정밀 치료제의 사용 확대라는 세 가지 요인에 기인합니다. 의료 정책과 보험 급여 제도, 그리고 병원의 암 치료 인프라 구축이 어우러져, 이 채널이 포괄적이고 유기적으로 연계된 치료 서비스를 제공할 수 있는 견고한 기반이 마련되었으며, 이에 따라 위암 치료제 시장의 성장이 촉진되고 있습니다.

목차

제1장 주요 요약

제2장 위암 치료제 시장 전망

제3장 경쟁 구도

제4장 위암 치료제 시장 : 주요 업계 역학

제5장 위암 치료제 시장 : 세계 시장 분석

제6장 위암 치료제 시장 매출 분석 : 유형별

제7장 위암 치료제 시장 매출 분석 : 치료별

제8장 위암 치료제 시장 매출 분석 : 표적치료제 및 면역치료제별

제9장 위암 치료제 시장 매출 분석 : 투여 경로별

제10장 위암 치료제 시장 매출 분석 : 유통 채널별

제11장 위암 치료제 시장 : 지역별 분석

제12장 위암 치료제 시장 업계 상황

제13장 위암 치료제 시장 : 주요 기업 개요

제14장 기타 분석 대상 기업 리스트

제15장 부록

KSM

The stomach cancer therapeutics market size is expected to grow from US$ 5.32 billion in 2025 to US$ 14.46 billion by 2034; it is projected to register a CAGR of 11.76% during 2026-2034.

The rising global incidence of stomach cancer, rapid uptake of PD-1/PD-L1 checkpoint inhibitors in combination regimens, and expansion of biomarker-driven testing and companion diagnostics are noteworthy factors contributing to the expansion of the stomach cancer therapeutics market size. Additionally, widespread integration of antibody-drug conjugates for enhanced tumor targeting, the rise of dual-target and bispecific immunotherapies, and full-scale adoption of AI and multiomics for personalized treatment pathways are projected to bring new stomach cancer therapeutics market trends in the near future.

Gastric cancer exhibits complex biological behavior because various genomic transcriptomic proteomic and epigenetic factors affect its development which makes standard treatment methods less successful. Through multiomics integration researchers gain complete tumor biological knowledge that enables them to find important biomarkers which include HER2 PD-L1 and CLDN18.2 that doctors use to select targeted therapies. AI enables researchers to examine extensive multiomics datasets which allow them to discover patterns and forecast treatment outcomes. AI models enable researchers to categorize patients based on their biomarker levels and molecular characteristics which allows them to choose between ADC treatments and immunotherapy treatments. Machine learning approaches currently assist researchers in ADC development because they help them select effective antibodies while maintaining stable linkers and creating powerful payloads which boosts drug design efficiency and clinical trial success rates. AI-based clinical decision support systems enable healthcare professionals to use patient-specific information which contains genetic data and treatment history to determine the most effective treatment options. This is particularly relevant in gastric cancer, where resistance to therapies like HER2 inhibitors or immune checkpoint inhibitors is common. AI systems improve treatment pathways through their continuous learning progress which helps develop adaptable therapy methods.

AI technology and multi-omics research work together to create precision oncology for gastric cancer which enables doctors to make better diagnoses and provide targeted treatments that lead to better patient results through customized treatment programs, thereby emerging as a significant trend in the stomach cancer therapeutics market.

Distribution Channel -Based Insights

Based on distribution channel, the stomach cancer therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest stomach cancer therapeutics market share in 2025. Hospital pharmacies are responsible for dispensing expensive and intricate oncology medications which require clinical environments for their application. The pharmacies establish links with oncologists and multidisciplinary tumor boards and infusion centers through their hospital-based operations which handle chemotherapy and immunotherapy and targeted therapy treatments. The system shows its most value when it needs to handle injectable drugs and parenteral drugs which need special storage solutions and permanent patient observation. Hospital pharmacies manage all aspects of advanced therapeutic drugs through their work with formulary selection and pharmacovigilance and purchasing activities. The market expansion results from three factors which include increased stomach cancer cases and growing oncology departments and the rising use of biologics and precision medicines which need clinical oversight. The combination of healthcare policies and reimbursement systems and hospital cancer care infrastructure development establishes a strong foundation for this channel to provide complete and coordinated treatment services, thereby fueling the stomach cancer therapeutics market growth.

The World Health Organization and Australian Institute of Health and Welfare are among the primary and secondary sources referred to while preparing the stomach cancer therapeutics market report.

Table Of Contents

1. Executive Summary

  • 1.1 Analyst Market Outlook
  • 1.2 Market Attractiveness

2. Stomach Cancer Therapeutics Market Landscape

  • 2.1 Overview
  • 2.2 Value Chain Analysis
    • 2.2.1 Raw Materials/Components
    • 2.2.2 Manufacturing Process/Technology
    • 2.2.3 Distribution Landscape
  • 2.3 Supply Chain Analysis
    • 2.3.1 List of Manufacturers/Suppliers
    • 2.3.2 List of Potential Customers (Upto 50)
  • 2.4 Porter's Five Force Analysis
    • 2.4.1 Competitive Rivalry - High
    • 2.4.2 Bargaining Power of Suppliers - Moderate
    • 2.4.3 Bargaining Power of Buyers - High
    • 2.4.4 Threat of Substitutes - Moderate
    • 2.4.5 Threat of New Entrants - Low
  • 2.5 PEST Analysis
  • 2.6 Import-Export Analysis for Key Countries (As per the nearest HS Code)
    • 2.6.1 Import-Export Analysis for Key Countries
  • 2.7 Impact of Artificial Intelligence (AI)
  • 2.8 Product or Technology Roadmap
  • 2.9 Sustainability and ESG Trends
    • 2.9.1 Environmental Trends
    • 2.9.2 Social Trends
    • 2.9.3 Governance Trends
  • 2.10 Patent Analysis
  • 2.11 Regulatory Framework

3. Competitive Landscape

  • 3.1 Company Benchmarking by Key Players
  • 3.2 Market Share Analysis, 2025 - By Key Players
  • 3.3 Market Concentration

4. Stomach Cancer Therapeutics Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Global Incidence of Stomach Cancer
    • 4.1.2 Rapid Uptake of PD-1/PD-L1 Checkpoint Inhibitors in Combination Regimens
    • 4.1.3 Expansion of Biomarker-Driven Testing and Companion Diagnostics
  • 4.2 Market Restraints
    • 4.2.1 High Costs of Premium Targeted and Immunotherapy Drugs
    • 4.2.2 Serious Side Effects Impacting Patient Tolerance and Outcomes
    • 4.2.3 Limited Reimbursement for Advanced Biomarker Testing
  • 4.3 Market Opportunities
    • 4.3.1 Geographic Diversification into High-Growth Emerging Markets
    • 4.3.2 Development and Scaling of Oral Formulations for Home-Based Care
    • 4.3.3 Early-Stage Disease Management with Neoadjuvant and Adjuvant Innovations
  • 4.4 Future Trends
    • 4.4.1 Widespread Integration of Antibody-Drug Conjugates for Enhanced Tumor Targeting
    • 4.4.2 Rise of Dual-Target and Bispecific Immunotherapies
    • 4.4.3 Full-Scale Adoption of AI and Multi-Omics for Personalized Treatment Pathways
  • 4.5 Impact of Drivers and Restraints

5. Stomach Cancer Therapeutics Market - Global Market Analysis

  • 5.1 Stomach Cancer Therapeutics Market Revenue (US$ Million), 2021-2034
  • 5.2 Stomach Cancer Therapeutics Market Forecast and Analysis

6. Stomach Cancer Therapeutics Market Revenue Analysis - Type

  • 6.1 Stomach Cancer Therapeutics Market Forecasts and Analysis by Type
    • 6.1.1 Adenocarcinomas
      • 6.1.1.1 Overview
      • 6.1.1.2 Adenocarcinomas: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 6.1.2 Gastrointestinal Tumors
      • 6.1.2.1 Overview
      • 6.1.2.2 Gastrointestinal Tumors: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 6.1.3 Neuroendocrine Tumors
      • 6.1.3.1 Overview
      • 6.1.3.2 Neuroendocrine Tumors: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 6.1.4 Lymphoma
      • 6.1.4.1 Overview
      • 6.1.4.2 Lymphoma: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 6.1.5 Others
      • 6.1.5.1 Overview
      • 6.1.5.2 Others: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)

7. Stomach Cancer Therapeutics Market Revenue Analysis - Treatment

  • 7.1 Stomach Cancer Therapeutics Market Forecasts and Analysis by Treatment
    • 7.1.1 Targeted and Immunotherapy Drugs
      • 7.1.1.1 Overview
      • 7.1.1.2 Targeted and Immunotherapy Drugs: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 7.1.2 Chemotherapy and Combination Drugs
      • 7.1.2.1 Overview
      • 7.1.2.2 Chemotherapy and Combination Drugs: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 7.1.3 Others
      • 7.1.3.1 Overview
      • 7.1.3.2 Others: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)

8. Stomach Cancer Therapeutics Market Revenue Analysis - Targeted And Immunotherapy Drugs

  • 8.1 Stomach Cancer Therapeutics Market Forecasts and Analysis by Targeted And Immunotherapy Drugs
    • 8.1.1 Human Epidermal Growth Factor Receptor (HER2)
      • 8.1.1.1 Overview
      • 8.1.1.2 Human Epidermal Growth Factor Receptor (HER2): Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 8.1.2 Monoclonal Antibody
      • 8.1.2.1 Overview
      • 8.1.2.2 Monoclonal Antibody: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 8.1.3 Checkpoint Inhibitors
      • 8.1.3.1 Overview
      • 8.1.3.2 Checkpoint Inhibitors: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)

9. Stomach Cancer Therapeutics Market Revenue Analysis - Route Of Administration

  • 9.1 Stomach Cancer Therapeutics Market Forecasts and Analysis by Route Of Administration
    • 9.1.1 Oral
      • 9.1.1.1 Overview
      • 9.1.1.2 Oral: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 9.1.2 Parenteral
      • 9.1.2.1 Overview
      • 9.1.2.2 Parenteral: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 9.1.3 Others
      • 9.1.3.1 Overview
      • 9.1.3.2 Others: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)

10. Stomach Cancer Therapeutics Market Revenue Analysis - Distribution Channel

  • 10.1 Stomach Cancer Therapeutics Market Forecasts and Analysis by Distribution Channel
    • 10.1.1 Hospital Pharmacy
      • 10.1.1.1 Overview
      • 10.1.1.2 Hospital Pharmacy: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 10.1.2 Retail Pharmacy
      • 10.1.2.1 Overview
      • 10.1.2.2 Retail Pharmacy: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)
    • 10.1.3 Online Pharmacy
      • 10.1.3.1 Overview
      • 10.1.3.2 Online Pharmacy: Stomach Cancer Therapeutics Market - Revenue, 2021-2034 (US$ Million)

11. Stomach Cancer Therapeutics Market - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Stomach Cancer Therapeutics Market Overview
    • 11.1.2 North America: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 11.1.3 North America: Stomach Cancer Therapeutics Market - By Segmentation
      • 11.1.3.1 Type
      • 11.1.3.2 Treatment
      • 11.1.3.3 Targeted And Immunotherapy Drugs
      • 11.1.3.4 Route Of Administration
      • 11.1.3.5 Distribution Channel
    • 11.1.4 North America: Stomach Cancer Therapeutics Market Breakdown by Countries
      • 11.1.4.1 United States Market
        • 11.1.4.1.1 United States: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.1.4.1.2 United States: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.1.4.1.2.1 Type
          • 11.1.4.1.2.2 Treatment
          • 11.1.4.1.2.3 Targeted And Immunotherapy Drugs
          • 11.1.4.1.2.4 Route Of Administration
          • 11.1.4.1.2.5 Distribution Channel
      • 11.1.4.2 Canada Market
        • 11.1.4.2.1 Canada: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.1.4.2.2 Canada: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.1.4.2.2.1 Type
          • 11.1.4.2.2.2 Treatment
          • 11.1.4.2.2.3 Targeted And Immunotherapy Drugs
          • 11.1.4.2.2.4 Route Of Administration
          • 11.1.4.2.2.5 Distribution Channel
      • 11.1.4.3 Mexico Market
        • 11.1.4.3.1 Mexico: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.1.4.3.2 Mexico: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.1.4.3.2.1 Type
          • 11.1.4.3.2.2 Treatment
          • 11.1.4.3.2.3 Targeted And Immunotherapy Drugs
          • 11.1.4.3.2.4 Route Of Administration
          • 11.1.4.3.2.5 Distribution Channel
  • 11.2 Europe
    • 11.2.1 Europe Stomach Cancer Therapeutics Market Overview
    • 11.2.2 Europe: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 11.2.3 Europe: Stomach Cancer Therapeutics Market - By Segmentation
      • 11.2.3.1 Type
      • 11.2.3.2 Treatment
      • 11.2.3.3 Targeted And Immunotherapy Drugs
      • 11.2.3.4 Route Of Administration
      • 11.2.3.5 Distribution Channel
    • 11.2.4 Europe: Stomach Cancer Therapeutics Market Breakdown by Countries
      • 11.2.4.1 Germany Market
        • 11.2.4.1.1 Germany: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.2.4.1.2 Germany: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.2.4.1.2.1 Type
          • 11.2.4.1.2.2 Treatment
          • 11.2.4.1.2.3 Targeted And Immunotherapy Drugs
          • 11.2.4.1.2.4 Route Of Administration
          • 11.2.4.1.2.5 Distribution Channel
      • 11.2.4.2 France Market
        • 11.2.4.2.1 France: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.2.4.2.2 France: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.2.4.2.2.1 Type
          • 11.2.4.2.2.2 Treatment
          • 11.2.4.2.2.3 Targeted And Immunotherapy Drugs
          • 11.2.4.2.2.4 Route Of Administration
          • 11.2.4.2.2.5 Distribution Channel
      • 11.2.4.3 United Kingdom Market
        • 11.2.4.3.1 United Kingdom: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.2.4.3.2 United Kingdom: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.2.4.3.2.1 Type
          • 11.2.4.3.2.2 Treatment
          • 11.2.4.3.2.3 Targeted And Immunotherapy Drugs
          • 11.2.4.3.2.4 Route Of Administration
          • 11.2.4.3.2.5 Distribution Channel
      • 11.2.4.4 Italy Market
        • 11.2.4.4.1 Italy: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.2.4.4.2 Italy: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.2.4.4.2.1 Type
          • 11.2.4.4.2.2 Treatment
          • 11.2.4.4.2.3 Targeted And Immunotherapy Drugs
          • 11.2.4.4.2.4 Route Of Administration
          • 11.2.4.4.2.5 Distribution Channel
      • 11.2.4.5 Spain Market
        • 11.2.4.5.1 Spain: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.2.4.5.2 Spain: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.2.4.5.2.1 Type
          • 11.2.4.5.2.2 Treatment
          • 11.2.4.5.2.3 Targeted And Immunotherapy Drugs
          • 11.2.4.5.2.4 Route Of Administration
          • 11.2.4.5.2.5 Distribution Channel
      • 11.2.4.6 Rest of Europe Market
        • 11.2.4.6.1 Rest of Europe: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.2.4.6.2 Rest of Europe: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.2.4.6.2.1 Type
          • 11.2.4.6.2.2 Treatment
          • 11.2.4.6.2.3 Targeted And Immunotherapy Drugs
          • 11.2.4.6.2.4 Route Of Administration
          • 11.2.4.6.2.5 Distribution Channel
  • 11.3 Asia Pacific
    • 11.3.1 Asia Pacific Stomach Cancer Therapeutics Market Overview
    • 11.3.2 Asia Pacific: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 11.3.3 Asia Pacific: Stomach Cancer Therapeutics Market - By Segmentation
      • 11.3.3.1 Type
      • 11.3.3.2 Treatment
      • 11.3.3.3 Targeted And Immunotherapy Drugs
      • 11.3.3.4 Route Of Administration
      • 11.3.3.5 Distribution Channel
    • 11.3.4 Asia Pacific: Stomach Cancer Therapeutics Market Breakdown by Countries
      • 11.3.4.1 China Market
        • 11.3.4.1.1 China: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.3.4.1.2 China: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.3.4.1.2.1 Type
          • 11.3.4.1.2.2 Treatment
          • 11.3.4.1.2.3 Targeted And Immunotherapy Drugs
          • 11.3.4.1.2.4 Route Of Administration
          • 11.3.4.1.2.5 Distribution Channel
      • 11.3.4.2 Japan Market
        • 11.3.4.2.1 Japan: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.3.4.2.2 Japan: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.3.4.2.2.1 Type
          • 11.3.4.2.2.2 Treatment
          • 11.3.4.2.2.3 Targeted And Immunotherapy Drugs
          • 11.3.4.2.2.4 Route Of Administration
          • 11.3.4.2.2.5 Distribution Channel
      • 11.3.4.3 India Market
        • 11.3.4.3.1 India: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.3.4.3.2 India: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.3.4.3.2.1 Type
          • 11.3.4.3.2.2 Treatment
          • 11.3.4.3.2.3 Targeted And Immunotherapy Drugs
          • 11.3.4.3.2.4 Route Of Administration
          • 11.3.4.3.2.5 Distribution Channel
      • 11.3.4.4 Australia Market
        • 11.3.4.4.1 Australia: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.3.4.4.2 Australia: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.3.4.4.2.1 Type
          • 11.3.4.4.2.2 Treatment
          • 11.3.4.4.2.3 Targeted And Immunotherapy Drugs
          • 11.3.4.4.2.4 Route Of Administration
          • 11.3.4.4.2.5 Distribution Channel
      • 11.3.4.5 South Korea Market
        • 11.3.4.5.1 South Korea: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.3.4.5.2 South Korea: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.3.4.5.2.1 Type
          • 11.3.4.5.2.2 Treatment
          • 11.3.4.5.2.3 Targeted And Immunotherapy Drugs
          • 11.3.4.5.2.4 Route Of Administration
          • 11.3.4.5.2.5 Distribution Channel
      • 11.3.4.6 Rest of Asia Pacific Market
        • 11.3.4.6.1 Rest of Asia Pacific: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.3.4.6.2 Rest of Asia Pacific: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.3.4.6.2.1 Type
          • 11.3.4.6.2.2 Treatment
          • 11.3.4.6.2.3 Targeted And Immunotherapy Drugs
          • 11.3.4.6.2.4 Route Of Administration
          • 11.3.4.6.2.5 Distribution Channel
  • 11.4 Middle East and Africa
    • 11.4.1 Middle East and Africa Stomach Cancer Therapeutics Market Overview
    • 11.4.2 Middle East and Africa: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 11.4.3 Middle East and Africa: Stomach Cancer Therapeutics Market - By Segmentation
      • 11.4.3.1 Type
      • 11.4.3.2 Treatment
      • 11.4.3.3 Targeted And Immunotherapy Drugs
      • 11.4.3.4 Route Of Administration
      • 11.4.3.5 Distribution Channel
    • 11.4.4 Middle East and Africa: Stomach Cancer Therapeutics Market Breakdown by Countries
      • 11.4.4.1 Saudi Arabia Market
        • 11.4.4.1.1 Saudi Arabia: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.4.4.1.2 Saudi Arabia: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.4.4.1.2.1 Type
          • 11.4.4.1.2.2 Treatment
          • 11.4.4.1.2.3 Targeted And Immunotherapy Drugs
          • 11.4.4.1.2.4 Route Of Administration
          • 11.4.4.1.2.5 Distribution Channel
      • 11.4.4.2 South Africa Market
        • 11.4.4.2.1 South Africa: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.4.4.2.2 South Africa: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.4.4.2.2.1 Type
          • 11.4.4.2.2.2 Treatment
          • 11.4.4.2.2.3 Targeted And Immunotherapy Drugs
          • 11.4.4.2.2.4 Route Of Administration
          • 11.4.4.2.2.5 Distribution Channel
      • 11.4.4.3 United Arab Emirates Market
        • 11.4.4.3.1 United Arab Emirates: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.4.4.3.2 United Arab Emirates: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.4.4.3.2.1 Type
          • 11.4.4.3.2.2 Treatment
          • 11.4.4.3.2.3 Targeted And Immunotherapy Drugs
          • 11.4.4.3.2.4 Route Of Administration
          • 11.4.4.3.2.5 Distribution Channel
      • 11.4.4.4 Rest of Middle East and Africa Market
        • 11.4.4.4.1 Rest of Middle East and Africa: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.4.4.4.2 Rest of Middle East and Africa: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.4.4.4.2.1 Type
          • 11.4.4.4.2.2 Treatment
          • 11.4.4.4.2.3 Targeted And Immunotherapy Drugs
          • 11.4.4.4.2.4 Route Of Administration
          • 11.4.4.4.2.5 Distribution Channel
  • 11.5 South and Central America
    • 11.5.1 South and Central America Stomach Cancer Therapeutics Market Overview
    • 11.5.2 South and Central America: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
    • 11.5.3 South and Central America: Stomach Cancer Therapeutics Market - By Segmentation
      • 11.5.3.1 Type
      • 11.5.3.2 Treatment
      • 11.5.3.3 Targeted And Immunotherapy Drugs
      • 11.5.3.4 Route Of Administration
      • 11.5.3.5 Distribution Channel
    • 11.5.4 South and Central America: Stomach Cancer Therapeutics Market Breakdown by Countries
      • 11.5.4.1 Brazil Market
        • 11.5.4.1.1 Brazil: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.5.4.1.2 Brazil: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.5.4.1.2.1 Type
          • 11.5.4.1.2.2 Treatment
          • 11.5.4.1.2.3 Targeted And Immunotherapy Drugs
          • 11.5.4.1.2.4 Route Of Administration
          • 11.5.4.1.2.5 Distribution Channel
      • 11.5.4.2 Argentina Market
        • 11.5.4.2.1 Argentina: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.5.4.2.2 Argentina: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.5.4.2.2.1 Type
          • 11.5.4.2.2.2 Treatment
          • 11.5.4.2.2.3 Targeted And Immunotherapy Drugs
          • 11.5.4.2.2.4 Route Of Administration
          • 11.5.4.2.2.5 Distribution Channel
      • 11.5.4.3 Rest of South and Central America Market
        • 11.5.4.3.1 Rest of South and Central America: Stomach Cancer Therapeutics Market Revenue and Forecasts, 2021-2034 (US$ Million)
        • 11.5.4.3.2 Rest of South and Central America: Stomach Cancer Therapeutics Market - By Segmentation
          • 11.5.4.3.2.1 Type
          • 11.5.4.3.2.2 Treatment
          • 11.5.4.3.2.3 Targeted And Immunotherapy Drugs
          • 11.5.4.3.2.4 Route Of Administration
          • 11.5.4.3.2.5 Distribution Channel

12. Stomach Cancer Therapeutics Market Industry Landscape

13. Stomach Cancer Therapeutics Market - Key Company Profiles

  • 13.1 Merck & Co Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Bristol-Myers Squibb Co
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Eli Lilly and Co
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Astellas Pharma Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Genentech Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 AstraZeneca Plc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Daiichi Sankyo Co Ltd
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Celltrion Inc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Biocon Biologics Ltd
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 BeOne Medicines GmbH
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. List of Additional Companies Analyzed

  • 14.1 List of Additional Companies Analyzed

15. Appendix

  • 15.1 Glossary
  • 15.2 Research Methodology and Approach
    • 15.2.1 Secondary Research
    • 15.2.2 Primary Research
    • 15.2.3 Market Estimation Approach
      • 15.2.3.1 Supply Side Analysis
      • 15.2.3.2 Demand Side Analysis
    • 15.2.4 Research Assumptions and Limitations
    • 15.2.5 Currency Conversion
  • 15.3 About The Insight Partners
  • 15.4 Market Intelligence Cloud
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
문의하기